Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 9/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5642447 | 0.92 | TP53 (0.45) | TP53LMNAMAPTF10PAK1 | |
| SCHEMBL5643391 | 0.87 | TP53 (0.56) | TP53LMNAMAPTF10POLB | |
| SCHEMBL5639536 | 0.86 | TP53 (0.54) | TP53LMNAMAPTF10POLB | |
| SCHEMBL4588111 | 0.81 | MAPK14 (0.42) | F10PAK1 | |
| SCHEMBL4586894 | 0.78 | F10 (0.43) | TP53F10KLKB1EGLN1 | |
| SCHEMBL4593936 | 0.77 | F10 (0.43) | F10PAK1 | |
| SCHEMBL4594684 | 0.77 | F10 (0.55) | TP53LMNAF10 | |
| SCHEMBL4586501 | 0.77 | KLKB1 (0.39) | F10PAK1KLKB1EGLN1 | |
| SCHEMBL5640760 | 0.76 | F10 (0.56) | LMNAF10 | |
| SCHEMBL4587434 | 0.76 | CTSL (0.46) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667647-A4 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1667647-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | TP53 4214/4885LMNA 774/4885MAPT 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.